Top pedigree leading Xcovery’s kinase inhibitors
With two leading biotech entrepreneurs and scientists at the helm, closely held Xcovery Holdings has a leg up as it continues development of next generation kinase inhibitors as treatments for cancer...
View ArticleJanney starts Veracyte at buy
Janney Capital Markets has initiated coverage of Veracyte (NASDAQ:VCYT) with a “buy” rating and fair value estimate of $25, saying the company is changing the paradigm of thyroid cancer diagnosis and...
View Article
More Pages to Explore .....